CSI Market
Sign In | Register

Revance Therapeutics Inc (RVNC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RVNC Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Revance Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-128.74
Depreciation & amortization4.66
Amortization of Other Assets3.52
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-10.30
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation19.37
Income (Loss) from Equity Method Investments0.00
Fair Value of Assets Acquired0.00
Conversion Of Convertible Preferred Stock Warrant-
Gain Loss On Warrant-
Interest Expense Debt-
Interest Costs Capitalized-
Modification Of Preferred Stock In Accordance With Settlement Agreement-
Derivative Liabilities Recognized As Result Of Settlement Agreement-
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Operating Results-
Issuance Of Common Stock For Services Operating Activities-
Issuance Of Preferred Stock For Services Operating Activities-
Conversion Of Preferred Stock Warrants To Common Stock Warrants-
Adjustments To Additional Paid In Capital Termination Of Repurchase Rights Related To Common Stock Issued Pursuant To Early Exercises-
Conversion Of Stock Amount Issued-
Debt Conversion Converted Instrument Amount-
Deemed Dividend On Redeemable Convertible Preferred Stock-
Rescission Of Note Receivable From Stockholder-
Issuance Of Convertible Preferred Stock Warrants-
Reclassification Of Convertible Preferred Stock Warrants To Liabilities-
Gain Loss On Derivative Instruments Net Pretax-
Gain Losson Derivative Instruments Contract Net Pretax-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction0.75
Increase Decreasein Deferred Rent-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-20.59
Increase (Decrease) in Accounts Payable-2.28
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-20.11
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.53
Other Working Capital0.07
Other Noncash Income (Expense)1.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities5.76
Discontinued operations0.00
Net Cash flow from Operating Activities-148.16
Investing Activities
Capital Expenditures-2.24
Sale of Capital Items0.00
Short-term Investments Proceeds-3.93
Short-term Investments Acq.0.00
Real Estate Investments0.00
Sale Leaseback Transaction Net Proceeds-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-9.13
Discontinued operations0.00
Net Cash Flow from Investing Activities-15.31
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.27
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.08
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net84.52
Repayments On Notes Receivable From Stockholders-
Proceeds From Issuance of Follow On Offering-
Proceeds From Issuance of Follow On Offering Net of Commissions and Discount-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities83.33
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-150.40
Total Cash Flow-80.14
4 historic quarters locked

Sign in to unlock the full Revance Therapeutics Inc cash flow history.

Sign In Create Free Account

About Revance Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001479290-24-000128

Figures are derived from filed reports and may be restated. Historical data is subject to revision.